Search Results

Market analysis Score 25 Bullish

Edwards Lifesciences Stock Shows Resilience Amid Market Volatility, Outpaces S&P 500 in 2024

Mar 09, 2026 16:17 UTC
EW, SPY, XLV
Short term

Edwards Lifesciences (EW) delivered a 22.3% gain in 2024 through March 8, surpassing the S&P 500's 14.7% return and the healthcare sector's 17.8% rise, driven by strong product adoption and earnings growth. The stock now trades at a premium valuation relative to its peers.

  • Edwards Lifesciences (EW) gained 22.3% in 2024 through March 8, outpacing the S&P 500 (14.7%) and XLV (17.8%)
  • TAVR revenue grew 28.4% YoY, contributing to 16.2% year-to-date share gain
  • Adjusted EPS rose 13.5% to $3.72 in 2023, beating estimates by 5.1%
  • Forward P/E of 34.8 is elevated versus S&P 500’s 22.1, reflecting premium growth expectations
  • Q1 2024 earnings release scheduled for April 24, 2024, expected to shape near-term outlook
  • Strong international reimbursement expansions in Germany and Japan supported global sales growth

Edwards Lifesciences (EW) has outperformed both the broader market and its sector in 2024, posting a 22.3% increase in share value as of March 8, 2024, compared to the S&P 500's 14.7% rise. The healthcare-focused company has maintained momentum despite sector-wide headwinds, recording a 16.2% year-to-date return in its core structural heart valve business and a 28.4% jump in revenue from its transcatheter aortic valve replacement (TAVR) portfolio. These gains were supported by steady U.S. and international device approvals and expanded reimbursement coverage in key markets, including Germany and Japan. The company's 2023 adjusted EPS rose 13.5% year-over-year to $3.72, exceeding analyst expectations by 5.1%, with operating margins improving to 35.4%. In contrast, the S&P 500 (SPY) gained 14.7% during the same period, while the healthcare sector ETF (XLV) posted a 17.8% return. Despite its strong performance, EW's forward P/E ratio now stands at 34.8, significantly above the S&P 500's 22.1, signaling investor optimism on long-term growth potential. Market participants are closely watching Edwards Lifesciences' Q1 2024 earnings release, scheduled for April 24, 2024, as guidance on TAVR uptake and new product launches could influence future positioning. The stock remains a top pick among healthcare investors, particularly within the medical device subsector, where it has outperformed peers such as Boston Scientific (BSX) and Medtronic (MDT).

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 65 Bullish

Berkshire Hathaway Proxy Filing Hints at Share Buyback Resumption

Mar 14, 13:03

Score 35 Bearish

How Much Lower Can Opendoor Technologies Stock Go?

Mar 14, 12:01

Score 65

Private Credit Faces 'Yellow Alert' Amid Shift in Regulatory Watch, Swedish Defense Gains 'Green Light'

Mar 14, 12:00

Score 45 Bearish

Mortgage and refinance interest rates today, March 14, 2026: These are not 'normal world' rates

Mar 14, 10:00

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Intelligence Terminal AI Assistant Trading Challenge Analysis Market News Pricing
Sign In Get Started
Home
Terminal
AI
Markets
Profile